Objectives: The aim of this study was to compare outcomes after percutaneous coronary intervention (PCI) with sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in the treatment of cardiac allograft vasculopathy (CAV).
Background: PCI in patients with CAV is associated with increased rates of restenosis compared with PCI in patients without CAV. There are no dedicated studies on the influence of different drug-eluting stents (DES) on the outcomes of patients with CAV.
Methods: This is a retrospective observational study of 108 consecutive patients with CAV who underwent PCI with SES and PES at UCLA Medical Center and University of Padova Medical Center between 2002 and 2008.
Results: Baseline characteristics were similar among SES (n = 68) and PES (n = 40) patients with the exception of older patients, larger minimal lumen diameter, and smaller diameter stenosis in the SES-treated patients. Angiographic follow-up at 1 year was high in the SES and PES groups (74% vs. 76%, p = 0.8). The SES and PES groups had similar binary restenosis rates (10% vs. 9%, p = 0.7), percent diameter stenosis (24 +/- 24% vs. 24 +/- 18%, p = 0.94), and late lumen loss (0.67 +/- 1.03 mm vs. 0.68 +/- 1.11 mm, p > 0.9). One-year clinical outcomes were not significantly different among CAV patients treated with either SES or PES (major adverse cardiac events: 10% vs. 15%, p = 0.5; death: 3% vs. 5%, p = 0.4; myocardial infarction: 3% vs. 5%, p = 0.4; target vessel revascularization: 4% vs. 8%, p = 0.3).
Conclusions: In patients who underwent PCI for CAV, both SES and PES were safe and effective with no significant differences in clinical and angiographic outcomes. Randomized clinical trials comparing different DES with longer follow-up are necessary to identify the optimal treatment strategy for patients with CAV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcin.2010.02.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease.
Alzheimers Dement
November 2024
Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Article Synopsis
- Diagnosing Alzheimer's disease is tough for doctors, which can lead to delays in getting the right care for patients.
- Blood tests that check for signs of Alzheimer's could help doctors find the disease earlier and treat it better, but there are still some big challenges to overcome.
- A special group of leaders in Alzheimer's research is working on solutions, like creating better guidelines, training healthcare workers, and making sure patients understand their test results.
Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease.
Alzheimers Dement
November 2024
Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, USA.
Article Synopsis
- Blood-based biomarkers (BBMs) are new tests that help doctors check for Alzheimer's disease in a simpler and cheaper way than older methods like brain scans or spinal fluid tests.! -
- A special group called the Global CEO Initiative on Alzheimer's Disease is suggesting two ways to use these BBMs: one for initial testing and another to confirm more serious cases.! -
- Using BBMs can make it easier for doctors to diagnose Alzheimer's, which means that patients can start getting needed treatments faster.!
Microplastics and Endocrine Disruptors in Typical Wastewater Treatment Plants in Megacity Shanghai.
Toxics
May 2024
College of Oceanography and Ecological Science, Shanghai Ocean University, Shanghai 201306, China.
The fast development of China's urbanization has led to a notable release of emerging pollutants, including microplastics (MPs) and endocrine disruptors (EDCs). Generally, these pollutants enter the coastal environment through the discharge of wastewater treatment plants (WWTPs) and finally threaten the organisms in the receiving waterbody. The study investigated the environmental behavior of MPs and EDCs in two typical WWTPs in one of the megacities in China, Shanghai.
View Article and Find Full Text PDFRecent Status of Phase I Clinical Trials for Brain Tumors: A Regulatory Science Study of Exploratory Efficacy Endpoints.
Ther Innov Regul Sci
July 2024
Department of Neurosurgery, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Background: Appropriate exploratory efficacy data from Phase I trials are vital for subsequent phases. Owing to the uniqueness of brain tumors (BTs), use of different strategies to evaluate efficacy is warranted. We studied exploratory efficacy evaluation in Phase I trials involving BTs.
View Article and Find Full Text PDFSmooth muscle differentiation of coronary intima in autopsy tissues after sirolimus-eluting stent implantation.
Cardiovasc Pathol
November 2023
Department of Molecular Pathology, Tokyo Medical University, Shinjuku, Tokyo, Japan.
Background: In coronary atherosclerotic disease, the proliferation of intimal smooth muscle cells (SMCs) is regarded as beneficial with respect to stable and unstable plaques, but is thought detrimental in discussions on coronary stent restenosis. To resolve this discrepancy, we focused on the quality, not quantity, of intimal SMCs in coronary atherosclerotic disease.
Methods: Autopsied coronary artery specimens from seven patients implanted with bare metal stents (BMS), three with paclitaxel-eluting stents (PES), and 10 with sirolimus (rapamycin)-eluting stents (SES) were immunostained for SMC markers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!